As we come to the holiday season there is a lot to be thankful for but some people are going to have a lot better Christmas than others. These "lucky schemers" have figured out a way to make millions by defrauding the Medicare Part D dry plan. A report released …
Read More »Diabetes In Control
Bristol-Myers Squibb Selling Global Diabetes Business
Bristol-Myers Squibb Selling Global Diabetes Business Bristol-Myers Squibb is selling its global diabetes business which includes the blockbuster drugs Byetta, Bydureon, and Onglyza, to AstraZeneca.
Read More »PROTECT iT – The Intelligent Texture Sock
PROTECT iT – The Intelligent Texture Sock Therapeutic diabetic socks help to relieve discomfort, provide warmth, and prevent bacterial growth. PROTECT iT, the "Intelligent Texture" sock has multi-zone construction providing increased protection for sore-prone areas with silver ions within the fibers to inhibit bacterial growth, fungus and odor.
Read More »Effectiveness of Bariatric Surgery
According to updated analyses of the effects of weight-loss surgery from 164 studies, following 161,756 patients aged about 46 with a BMI of 46, BMI loss five years after surgery ranged from 12% to 17%, complication rates ranged from 10% to 17%, and the reoperation rate was about 7%. Among …
Read More »Older Women Are Sedentary a Majority of Their Day
Among more than 7,200 older women, the average amount of time spent in sedentary behavior was 9.7 hours each day, or 65.5% of their waking hours. Researchers noted that about one-third of sedentary periods lasted approximately 30 minutes. JAMA 2013;310:2562-3
Read More »Many Diabetes Patients Choose Secure Messaging But Few Are Responsive
In a recent study, secure messaging was the most popular choice for diabetes patients in post education programs, followed by in-person and phone-based interventions. However, fewer patients in the secure messaging arm finished the intervention compared with the other group, researchers found. The complexity of secure messaging may have played …
Read More »Insulin/Liraglutide Combo in Type 2 Diabetes
A potential new treatment option for T2 diabetes….
Read More »Insulin Glargine U300 versus Lantus
New preliminary data is in…. Sanofi, the maker of Lantus (insulin glargine), finished more phase III studies on their newest formulation of insulin glargine, U300, and discussed their results at the World Diabetes Congress 2013 in early December. The study results have not yet been published but researchers reported that the …
Read More »Liraglutide and Pancreatitis/Pancreatic Cancer Risk
Post market study results….
Read More »Diet Drinks and Cardiometabolic Disease
What the studies really say….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.